Evidence map›Paper›PMID 40810380›Full record

ArticleThe Journal of pathology2025

STING inhibition alleviates experimental peritoneal damage: potential therapeutic relevance for peritoneal dialysis.

Vanessa Marchant, Jorge García-Giménez, Guadalupe T González-Mateo, Pilar Sandoval, Lucía Tejedor-Santamaria, Sandra Rayego-Mateos, Ricardo Ramos, José A Jiménez-Heffernan, Alberto Ortiz, Anne-Catherine Raby and 3 more

Abstract read
In one paragraph

Article in The Journal of pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Vanessa MarchantCellular and Molecular Biology in Renal and Vascular Pathology Laboratory, Health Research Institute-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain.ORCID 0000-0002-2767-0229
Jorge García-GiménezRICORS2040, Madrid, Spain.
Guadalupe T González-MateoTissue and Organ Homeostasis Program, Centro de Biología Molecular Severo Ochoa (CBM), CSIC - Universidad Autónoma de Madrid, Madrid, Spain.
Pilar SandovalTissue and Organ Homeostasis Program, Centro de Biología Molecular Severo Ochoa (CBM), CSIC - Universidad Autónoma de Madrid, Madrid, Spain.
Lucía Tejedor-SantamariaCellular and Molecular Biology in Renal and Vascular Pathology Laboratory, Health Research Institute-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain.
Sandra Rayego-MateosCellular and Molecular Biology in Renal and Vascular Pathology Laboratory, Health Research Institute-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain.ORCID 0000-0001-6874-2359
Ricardo RamosIMDEA Food Institute, Universidad Autónoma de Madrid, Madrid, Spain.
José A Jiménez-HeffernanServicio de Anatomía Patológica, Hospital de la Princesa, Madrid, Spain.
Alberto OrtizRICORS2040, Madrid, Spain.
Anne-Catherine RabyWales Kidney Research Unit, Division of Infection & Immunity, School of Medicine, Cardiff University, Cardiff, UK.
Manuel López-CabreraTissue and Organ Homeostasis Program, Centro de Biología Molecular Severo Ochoa (CBM), CSIC - Universidad Autónoma de Madrid, Madrid, Spain.ORCID 0000-0002-0976-9719
Adrián M Ramos *RICORS2040, Madrid, Spain.ORCID 0000-0003-2718-3591
Marta Ruiz-Ortega *Cellular and Molecular Biology in Renal and Vascular Pathology Laboratory, Health Research Institute-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain.ORCID 0000-0002-1495-6535

Funding

Comunidad Autónoma de Madrid INNOREN P2022/BMD-7221European Union - NextGenerationEU, Mecanismo para la Recuperación y la Resiliencia PI20/00140European Union - NextGenerationEU, Mecanismo para la Recuperación y la Resiliencia PI21/01453European Union - NextGenerationEU, Mecanismo para la Recuperación y la Resiliencia PI23/00394European Union - NextGenerationEU, Mecanismo para la Recuperación y la Resiliencia RD21/0005/0002European Union - NextGenerationEU, Mecanismo para la Recuperación y la Resiliencia RD21/0005/0018European Union - NextGenerationEU, Mecanismo para la Recuperación y la Resiliencia RD24/0004/0001European Union - NextGenerationEU, Mecanismo para la Recuperación y la Resiliencia RD24/0004/0021Instituto de Salud Carlos III CP23/00025Marie Skłodowska-Curie IMPROVE-PD 812699
6 · The paper itself

Abstract

Peritoneal dialysis (PD) is a widely used kidney replacement therapy for patients with end-stage kidney disease. Nevertheless, long-term exposure to PD fluid can damage the peritoneal membrane, leading to ultrafiltration failure and, ultimately, discontinuation of PD. Investigation of the molecular mechanisms underlying this damage is essential for identifying new therapeutic targets to mitigate peritoneal deterioration in PD patients. To this end, we employed RNA sequencing in a preclinical model of peritoneal injury, induced by prolonged chlorhexidine (CHX) exposure, which revealed cytosolic DNA-sensing signaling as a novel pathway. Next, we demonstrated that key players in this pathway, such as the stimulator of interferon genes (STING) and its downstream signaling effectors (interferon regulatory factor 3, interferon-stimulated genes, and nuclear factor-κB signaling), were upregulated in experimental peritoneal damage. Moreover, increased STING expression was observed in human peritoneal biopsies from patients with PD. Subsequent studies in STING-deficient mice showed reduced proinflammatory gene expression and immune cell infiltration, together with inhibited nuclear factor-κB pathway activation at both early (10 days) and late (30 days) stages of CHX-induced peritoneal injury. STING deficiency also reduced peritoneal membrane thickening, fibrosis, and mesothelial-to-mesenchymal transition (MMT)-related changes in advanced CHX-induced damage. Furthermore, pharmacological inhibition of STING with C-176 attenuated CHX-induced peritoneal inflammation. Macrophages were identified as one of the STING-expressing cell types in the injured peritoneum. Hence, in vitro STING blockade in activated macrophages inhibited MMT in cultured mesothelial cells, suggesting that STING activation in this population may drive peritoneal fibrosis. Additionally, STING deficiency reduced peritoneal inflammation in S. epidermidis-induced peritonitis and decreased adhesion scores in a postsurgical intra-abdominal adhesion model. These findings identify STING as a pivotal mediator of peritoneal injury and support its potential as a novel therapeutic target to prevent PD-associated ultrafiltration failure. © 2025 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.

Indexed as

Membrane ProteinsPeritoneal DialysisPeritoneumAnimalsChlorhexidineDialysis SolutionsDisease Models, AnimalEpithelial-Mesenchymal TransitionFemaleHumansMaleMiceMice, Inbred C57BLMice, KnockoutNF-kappa BPeritoneal FibrosisChlorhexidineDialysis SolutionsMembrane ProteinsNF-kappa BSTING1 protein, humanSting1 protein, mouseSTING Proteincytosolic DNA‐sensing pathwayfibrosisinflammationperitoneal adhesionsperitoneal damageperitoneal dialysisperitonitisSTING signaling

Identifiers

PMID40810380
PMCPMC12438029

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.